Author: admin

The Alport Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Alport Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alport Syndrome Market.

Some of the key takeaways from the Alport Syndrome Pipeline Report:

• Companies across the globe are diligently working toward developing novel Alport Syndrome treatment therapies with a considerable amount of success over the years. 

• Alport Syndrome companies working in the treatment market are Enyo Pharma, Calliditas Therapeutics, River 3 Renal Corp., Travere Therapeutics, Inc., Chinook Therapeutics, Inc., Eloxx Pharmaceuticals, Novartis, Bayer, Evotec, and others, are developing therapies for the Alport Syndrome treatment 

• Emerging Alport Syndrome therapies in the different phases of clinical trials are- Vonafexor, Setanaxib, R3R01, Sparsentan, Atrasentan, ELX-02, and others are expected to have a significant impact on the Alport Syndrome market in the coming years.   

• In January 2024, ENYO Pharma (“ENYO”) has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its Investigational New Drug (IND) application, allowing the company to begin a Phase 2 clinical trial of Vonafexor, a highly selective FXR agonist, aimed at treating Alport Syndrome.

Alport Syndrome Overview

Alport Syndrome is a genetic disorder that affects the kidneys, ears, and eyes. It is caused by mutations in the genes responsible for producing collagen, a protein crucial for the structure of tissues. The syndrome leads to progressive kidney disease, hearing loss, and eye abnormalities. In severe cases, it can result in end-stage kidney failure. Alport Syndrome primarily affects males, though females can also experience symptoms, typically milder. Diagnosis is confirmed through genetic testing, and treatment focuses on managing symptoms, delaying kidney damage, and improving quality of life through medications and, in some cases, kidney transplantation.

Get a Free Sample PDF Report to know more about Alport Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/alport-syndrome-pipeline-insight

Emerging Alport Syndrome Drugs Under Different Phases of Clinical Development Include:

• Vonafexor: Enyo Pharma

• Setanaxib: Calliditas Therapeutics

• R3R01: River 3 Renal Corp.

• Sparsentan: Travere Therapeutics, Inc.

• Atrasentan: Chinook Therapeutics, Inc.

• ELX-02: Eloxx Pharmaceuticals

Alport Syndrome Route of Administration

Alport Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Alport Syndrome Molecule Type

Alport Syndrome Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Alport Syndrome Pipeline Therapeutics Assessment

• Alport Syndrome Assessment by Product Type

• Alport Syndrome By Stage and Product Type

• Alport Syndrome Assessment by Route of Administration

• Alport Syndrome By Stage and Route of Administration

• Alport Syndrome Assessment by Molecule Type

• Alport Syndrome by Stage and Molecule Type

DelveInsight’s Alport Syndrome Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Alport Syndrome product details are provided in the report. Download the Alport Syndrome pipeline report to learn more about the emerging Alport Syndrome therapies

Some of the key companies in the Alport Syndrome Therapeutics Market include:

Key companies developing therapies for Alport Syndrome are – Invitae Corporation, Illumina Inc, Natera Inc, PerkinElmer Inc, Quest Diagnostics Incorporated, Centogene N.V., Eurofins Discovery, Hoffmann-La Roche Ltd., Eurofins LifeCodexx GmbH, Ravgen, AstraZeneca, Lilly, Mylan N.V., Sanofi, Teva Pharmaceutical Industries Ltd., and others.

Alport Syndrome Pipeline Analysis:

The Alport Syndrome pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Alport Syndrome with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alport Syndrome Treatment.

• Alport Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Alport Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alport Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Alport Syndrome drugs and therapies

Alport Syndrome Pipeline Market Drivers

• Increasing Research and Development, Technological Advancements, Rising Awareness, FDA and Regulatory Approvals, Collaborations and Partnerships, are some of the important factors that are fueling the Alport Syndrome Market.

Alport Syndrome Pipeline Market Barriers

• However, Limited Patient Population, High Development Costs, High Development Costs, Lack of Awareness, Clinical Trial Challenges, and other factors are creating obstacles in the Alport Syndrome Market growth.

Scope of Alport Syndrome Pipeline Drug Insight    

• Coverage: Global

• Key Alport Syndrome Companies: Enyo Pharma, Calliditas Therapeutics, River 3 Renal Corp., Travere Therapeutics, Inc., Chinook Therapeutics, Inc., Eloxx Pharmaceuticals, Novartis, Bayer, Evotec, and others

• Key Alport Syndrome Therapies: Vonafexor, Setanaxib, R3R01, Sparsentan, Atrasentan, ELX-02, and others

• Alport Syndrome Therapeutic Assessment: Alport Syndrome current marketed and Alport Syndrome emerging therapies

• Alport Syndrome Market Dynamics: Alport Syndrome market drivers and Alport Syndrome market barriers 

Request for Sample PDF Report for Alport Syndrome Pipeline Assessment and clinical trials

Table of Contents

1. Alport Syndrome Report Introduction

2. Alport Syndrome Executive Summary

3. Alport Syndrome Overview

4. Alport Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Alport Syndrome Pipeline Therapeutics

6. Alport Syndrome Late Stage Products (Phase II/III)

7. Alport Syndrome Mid Stage Products (Phase II)

8. Alport Syndrome Early Stage Products (Phase I)

9. Alport Syndrome Preclinical Stage Products

10. Alport Syndrome Therapeutics Assessment

11. Alport Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Alport Syndrome Key Companies

14. Alport Syndrome Key Products

15. Alport Syndrome Unmet Needs

16 . Alport Syndrome Market Drivers and Barriers

17. Alport Syndrome Future Perspectives and Conclusion

18. Alport Syndrome Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alport Syndrome Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Enyo Pharma, Calliditas Therapeutics, Travere Therapeutics, Inc.

The Beta Thalassemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Beta Thalassemia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Beta Thalassemia Market.

Some of the key takeaways from the Beta Thalassemia Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Beta Thalassemia treatment therapies with a considerable amount of success over the years. 

• Beta Thalassemia companies working in the treatment market are Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others, are developing therapies for the Beta Thalassemia treatment 

• Emerging Beta Thalassemia therapies in the different phases of clinical trials are- PYRUKYND (mitapivat), CTX001, SP-420, EDIT-301, dimethylbutyrate, ACE-536, Luspatercept, Bitopertin, Deferitrin (GT56-252), ICL670, Emeramide, SP-420, Luspatercept, DST-0509, Mitapivat, SPD602, and others are expected to have a significant impact on the Beta Thalassemia market in the coming years.   

• In April 2024, Bristol Myers Squibb (BMY) announced that the European Commission (EC) has approved an expansion of the label for Reblozyl (luspatercept).

• In January 2024, Agios Pharmaceuticals‘ mitapivat achieved the primary and two key secondary endpoints in the Phase III ENERGIZE trial involving patients with non-transfusion-dependent alpha- or beta-thalassemia. The regulatory submission will also incorporate data from the second Phase III ENERGIZE-T study (NCT04770779), which focuses on adults with transfusion-dependent alpha- or beta-thalassemia.

Beta Thalassemia Overview

Beta thalassemia is a genetic blood disorder that reduces the production of hemoglobin, a protein in red blood cells that carries oxygen throughout the body. It results from mutations in the HBB gene, which provides instructions for making the beta-globin subunit of hemoglobin. This disorder leads to a deficiency in the beta-globin chains, causing the red blood cells to become malformed and break down prematurely, leading to anemia.

Get a Free Sample PDF Report to know more about Beta Thalassemia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/beta-thalassemia-pipeline-insight

Emerging Beta Thalassemia Drugs Under Different Phases of Clinical Development Include:

• PYRUKYND (mitapivat): Agios Pharmaceuticals

• CTX001: Vertex Pharmaceuticals

• SP-420: Pharmacosmos

• EDIT-301: Editas Medicine

• dimethylbutyrate: HemaQuest Pharmaceuticals

• ACE-536: Acceleron Pharma

• Luspatercept: Bristol-Myers Squibb

• Bitopertin: Hoffmann-La Roche

• Deferitrin (GT56-252): Sanofi

• ICL670: Novartis

• Emeramide: EmeraMed

• SP-420: Pharmacosmos A/S

• Luspatercept: Celgene

• DST-0509: DisperSol Technologies, LLC

• Mitapivat: Agios Pharmaceuticals

• SPD602: Shire

Beta Thalassemia Route of Administration

Beta Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Beta Thalassemia Molecule Type

Beta Thalassemia Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Beta Thalassemia Pipeline Therapeutics Assessment

• Beta Thalassemia Assessment by Product Type

• Beta Thalassemia By Stage and Product Type

• Beta Thalassemia Assessment by Route of Administration

• Beta Thalassemia By Stage and Route of Administration

• Beta Thalassemia Assessment by Molecule Type

• Beta Thalassemia by Stage and Molecule Type

DelveInsight’s Beta Thalassemia Report covers around 22+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Beta Thalassemia product details are provided in the report. Download the Beta Thalassemia pipeline report to learn more about the emerging Beta Thalassemia therapies

Some of the key companies in the Beta Thalassemia Therapeutics Market include:

Key companies developing therapies for Beta Thalassemia are – Ionis Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Silence Therapeutics plc, Phoenicia Biosciences, Shanghai BDgene, Beam Therapeutics, EmeraMed, CRISPR Therapeutics, CSL Vifor, EdiGene (GuangZhou) Inc., Regenacy Pharmaceuticals, Editas Medicine, Fulcrum Therapeutics, Allife Medical Science and Technology, Global Blood Therapeutics, Inc, Orchard Therapeutics, Acceleron Pharma, Disc Medicine, BRL Medicine, Celgene, and others.

Beta Thalassemia Pipeline Analysis:

The Beta Thalassemia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Beta Thalassemia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Beta Thalassemia Treatment.

• Beta Thalassemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Beta Thalassemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Beta Thalassemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Beta Thalassemia drugs and therapies

Beta Thalassemia Pipeline Market Strengths

• Strong pipeline activity with potential Phase III and phase II emerging therapies.

• Increasing prevalence and awareness of beta thalassemia

Beta Thalassemia Pipeline Market Opportunities

• Lack of any curative treatment options despite the launch of gene therapies which are subject to patient outcome assessment

• Improved national blood policies

• Advancement in genetic engineering because gene therapy has been hypothesized to serve as an effective cure for monogenic blood disorders for several decades

Scope of Beta Thalassemia Pipeline Drug Insight    

• Coverage: Global

• Key Beta Thalassemia Companies: Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others

• Key Beta Thalassemia Therapies: PYRUKYND (mitapivat), CTX001, SP-420, EDIT-301, dimethylbutyrate, ACE-536, Luspatercept, Bitopertin, Deferitrin (GT56-252), ICL670, Emeramide, SP-420, Luspatercept, DST-0509, Mitapivat, SPD602, and others

• Beta Thalassemia Therapeutic Assessment: Beta Thalassemia current marketed and Beta Thalassemia emerging therapies

• Beta Thalassemia Market Dynamics: Beta Thalassemia market drivers and Beta Thalassemia market barriers 

Request for Sample PDF Report for Beta Thalassemia Pipeline Assessment and clinical trials

Table of Contents

1. Beta Thalassemia Report Introduction

2. Beta Thalassemia Executive Summary

3. Beta Thalassemia Overview

4. Beta Thalassemia- Analytical Perspective In-depth Commercial Assessment

5. Beta Thalassemia Pipeline Therapeutics

6. Beta Thalassemia Late Stage Products (Phase II/III)

7. Beta Thalassemia Mid Stage Products (Phase II)

8. Beta Thalassemia Early Stage Products (Phase I)

9. Beta Thalassemia Preclinical Stage Products

10. Beta Thalassemia Therapeutics Assessment

11. Beta Thalassemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Beta Thalassemia Key Companies

14. Beta Thalassemia Key Products

15. Beta Thalassemia Unmet Needs

16 . Beta Thalassemia Market Drivers and Barriers

17. Beta Thalassemia Future Perspectives and Conclusion

18. Beta Thalassemia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Beta Thalassemia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight| Ionis Pharma, Agios Pharma, Silence Therapeutics, Phoenicia Bioscience

The Biliary Tract Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Biliary Tract Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Biliary Tract Cancer Market.

Some of the key takeaways from the Biliary Tract Cancer Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Biliary Tract Cancer treatment therapies with a considerable amount of success over the years. 

• Biliary Tract Cancer companies working in the treatment market are Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others, are developing therapies for the Biliary Tract Cancer treatment 

• Emerging Biliary Tract Cancer therapies in the different phases of clinical trials are- Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others are expected to have a significant impact on the Biliary Tract Cancer market in the coming years.   

• In April 2024, AstraZeneca has released updated exploratory findings from the TOPAZ-1 Phase III clinical trial, showing that Imfinzi (durvalumab), combined with standard-of-care chemotherapy, provided a long-term overall survival (OS) benefit in patients with advanced biliary tract cancer (BTC) at the three-year mark.

• In December 2023, RenovoRx, a clinical-stage biopharmaceutical company, has chosen Oklahoma University (OU) Health as the initial study center for its Phase III CouGar Trial of RenovoGem for treating bile duct cancer. The trial will evaluate RenovoGem specifically for unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA). This pivotal, randomized trial aims to assess the efficacy and safety of trans-arterial micro-perfusion (TAMP) using the RenovoGem delivery system in combination with gemcitabine and intravenous durvalumab for treating unresectable, locally advanced eCCA.

• In December 2023, The Scottish Medicines Consortium and the UK’s National Institute of Health and Care Excellence (NICE) have endorsed AstraZeneca’s durvalumab (Imfinzi) as a first-line treatment for adults with advanced biliary tract cancers in England and Scotland. This immunotherapy should be administered alongside the chemotherapy drugs gemcitabine and cisplatin.

Biliary Tract Cancer Overview

Biliary tract cancer, also known as cholangiocarcinoma, is a type of cancer that arises in the bile ducts, which are the tubes that carry bile (a digestive fluid) from the liver to the gallbladder and small intestine.

Get a Free Sample PDF Report to know more about Biliary Tract Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-pipeline-insight

Emerging Biliary Tract Cancer Drugs Under Different Phases of Clinical Development Include:

• Keytruda (pembrolizumab): Merck Sharp & Dohme

• Imfinzi (durvalumab): AstraZeneca

• Futibatinib (TAS-120): Taiho Oncology

• Melphalan: Delcath Systems

• E7090 (tasurgratinib): Eisai

• TT-00420: TransThera Sciences (Nanjing)

• ARQ 087 (Derazantinib): Basilea Pharmaceutica

• Lenvima (lenvatinib): Eisai and Merck & Co

• Zanidatamab: Zymeworks and BeiGene

• XmAb20717: Xencor, Inc.

• Nivolumab + DKN-01: Bristol-Myers Squibb/Leap Therapeutics, Inc.

• CTX-009: Compass Therapeutics

• MEDI5752: AstraZeneca

• Brigimadlin: Boehringer Ingelheim

• ZB131: ZielBio, Inc.

• GQ1001: GeneQuantum Healthcare (Suzhou) Co., Ltd.

• BNT141: BioNTech SE

• SO-C101: SOTIO Biotech

• CT-0508: Carisma Therapeutics Inc

• RAIN-32: Rain Oncology Inc

• AVA6000: Avacta Life Sciences Ltd

• DB-1303: DualityBio Inc.

Biliary Tract Cancer Route of Administration

Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Biliary Tract Cancer Molecule Type

Biliary Tract Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Biliary Tract Cancer Pipeline Therapeutics Assessment

• Biliary Tract Cancer Assessment by Product Type

• Biliary Tract Cancer By Stage and Product Type

• Biliary Tract Cancer Assessment by Route of Administration

• Biliary Tract Cancer By Stage and Route of Administration

• Biliary Tract Cancer Assessment by Molecule Type

• Biliary Tract Cancer by Stage and Molecule Type

DelveInsight’s Biliary Tract Cancer Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Biliary Tract Cancer product details are provided in the report. Download the Biliary Tract Cancer pipeline report to learn more about the emerging Biliary Tract Cancer therapies

Some of the key companies in the Biliary Tract Cancer Therapeutics Market include:

Key companies developing therapies for Biliary Tract Cancer are – Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene, and others.

Biliary Tract Cancer Pipeline Analysis:

The Biliary Tract Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Biliary Tract Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Biliary Tract Cancer Treatment.

• Biliary Tract Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Biliary Tract Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Biliary Tract Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Biliary Tract Cancer drugs and therapies 

Biliary Tract Cancer Pipeline Market Strengths

• The therapeutic landscape in BTCs has expanded considerably in recent years. Combined therapy with chemotherapy, immunotherapy, and modulation of immune checkpoints-mediated signaling pathways are promising strategies.

Biliary Tract Cancer Pipeline Market Opportunities

• Increasing cognizance about different mutations, pathways, and other regimens has changed the focus on curable treatment options with emerging candidates that will lead the growth of the global market.

Scope of Biliary Tract Cancer Pipeline Drug Insight    

• Coverage: Global

• Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others

• Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others

• Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies

• Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers 

Request for Sample PDF Report for Biliary Tract Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Biliary Tract Cancer Report Introduction

2. Biliary Tract Cancer Executive Summary

3. Biliary Tract Cancer Overview

4. Biliary Tract Cancer- Analytical Perspective In-depth Commercial Assessment

5. Biliary Tract Cancer Pipeline Therapeutics

6. Biliary Tract Cancer Late Stage Products (Phase II/III)

7. Biliary Tract Cancer Mid Stage Products (Phase II)

8. Biliary Tract Cancer Early Stage Products (Phase I)

9. Biliary Tract Cancer Preclinical Stage Products

10. Biliary Tract Cancer Therapeutics Assessment

11. Biliary Tract Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Biliary Tract Cancer Key Companies

14. Biliary Tract Cancer Key Products

15. Biliary Tract Cancer Unmet Needs

16 . Biliary Tract Cancer Market Drivers and Barriers

17. Biliary Tract Cancer Future Perspectives and Conclusion

18. Biliary Tract Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, MOA, ROA by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Incyte Crp